<DOC>
	<DOCNO>NCT00119457</DOCNO>
	<brief_summary>The purpose study determine whether TTP889 prevents venous thromboembolism follow surgery repair hip fracture .</brief_summary>
	<brief_title>Factor IX Inhibition Thrombosis Prevention ( The FIXIT Trial )</brief_title>
	<detailed_description>FIXIT first Phase 2 study TTP889 . The trial proof-of-concept study determine safety antithrombotic efficacy TTP889 patient risk venous thromboembolism ( VTE ) . The study multi-center , randomize , double-blind , parallel-group evaluation 300 mg TTP889 placebo , administer orally daily three week , patient undergone surgery repair unilateral fracture upper third either femur complete 5 9 day postoperative prophylactic treatment VTE .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Embolism Thrombosis</mesh_term>
	<criteria>Must undergone reparative surgery within 72 hour unilateral hip fracture , defined fracture upper third either femur Must start standard prophylactic treatment VTE low molecular weight heparin ( LMWH ) heparin surgery within 24 hour hip fracture surgery , continue treatment LMWH heparin least five day , nine day , surgery Last dose LMWH heparin must administer least 12 hour , 48 hour , dose study drug Females must negative serum pregnancy test Must weigh least 45 kg Must demonstrate mental physical ability willingness follow studyspecific instruction Must able read , comprehend sign Ethics Committeeapproved inform consent form Evidence active bleed Clinical sign VTE Any medical requirement ( intention use ) continue anticoagulation randomization end study History intracranial bleeding , hemorrhagic stroke , gastrointestinal bleeding within 3 month study start Presence active malignant disease Hip fracture associate multiple trauma , place patient excessive risk hemorrhage organ system failure , may make difficult impossible perform bilateral low limb venography Intention take aspirin dos great 325 mg/day Hemoglobin &lt; 5.45 mmol/L ( 9 g/dL ) , hematocrit &lt; 29 % , platelet count &lt; 100,000/mL screen visit Elevated ALT AST level &gt; 3.0 time ULN , elevate total bilirubin &gt; 1.5 ULN screen visit Creatinine &gt; 180 mmol/L ( 2.0 mg/dL ) screen visit Any laboratory value screen Investigator considers clinically significant warrant exclusion study Patient currently breast feed child wish continue breast feed Previous allergy contrast material contraindication perform bilateral low limb venography The use another investigational drug within 28 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>antithrombotic agent</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>embolism</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>hip fracture</keyword>
</DOC>